The combination of PARP/HDACi and anti-PD-L1 studies showed that both PARP/HDACi and anti-PD-L1 restricted tumor growth, but the combined treatment demonstrated a better therapeutic outcome than each treatment alone (Fig. 6I–K and Fig. S5). Here, CD274 is linked to neoplasm.